Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S39-S40. doi: 10.21037/tlcr.2017.10.16.

Authors

Aaron Lisberg¹, Edward B Garon¹

Affiliation

¹ Translational Oncology Research Laboratory, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

No abstract available

Publication types

Editorial
Comment